AstraZeneca was previously considered the black sheep among the corona vaccines and was only vaccinated in Germany to those under 65 years of age. A study showed that the British-Swedish vaccine is said to be even more effective in the elderly. STIKO has now given the green light for the AstraZeneca vaccine for over-65s.
Table of Contents
AstraZeneca vaccination released for older people
The Standing Vaccination Committee (STIKO) of the Robert Koch Institute (RKI) has published a new communication on AstraZeneca’s corona vaccine, in which it confirms the safety and effectiveness of the British-Swedish vaccine for older people as well. The STIKO therefore recommends vaccinating the group of over-65s with the AstraZeneca vaccine against the coronavirus with immediate effect. The initially frowned upon vaccine is now approved for all age groups.
The approval also applies to the period in which the two necessary vaccine doses must be vaccinated. With the AstraZeneca remedy, the interval is optimally 12 weeks. People who have already had Corona should be vaccinated no earlier than six months after diagnosis and should only receive a single vaccination.
AstraZeneca has so far only been vaccinated to younger people under the age of 65 for safety reasons and due to a lack of data. Now a pre-print study by the British Department of Health ” Public Health England ” shows that AstraZeneca is said to be even more effective than the BioNTech/Pfizer vaccine in older people.
AstraZeneca vaccine even more effective in the elderly
The study examined data on over 140,000 subjects aged 70 and over . About 75,000 of them were vaccinated with the AstraZeneca vaccine . After the first dose , the vaccine was 60 percent effective in the subjects after 28 to 34 days. After 35 days, the effectiveness was 70 percent . It was even higher than that of the first BioNTech/Pfizer dose.
The vaccination protected 60 to 73 percent of the subjects from any Covid 19 symptoms. In the group of over 80-year-olds, it even protected more than 80 percent of those vaccinated from hospitalization.
The pre-print study has yet to go through the peer review process. The data for the second vaccination dose are also not yet available. However, the results so far give hope and could also speed up approval for older people in Germany.
All about: The vaccine from AstraZeneca >>
